Pfizer’s chief strategist Andrew Baum, M.D., is leaving his post two years after pivoting from a career-long tenure as a ...

There might be room for two titans in the obesity business, but a third player might have a uniquely marketable option.

April 20 (Reuters) - Pfizer's Chief Strategy and Innovation Officer, Andrew Baum, is transitioning to a new role and will ...

Andrew Baum, a former Citi analyst, has left his role as Pfizer's executive vice president and chief strategy and innovation ...

U.S. Food and Drug Administration "enforcement in the social media space has historically been somewhat limited, but recent ...

Merck, Pfizer and Astellas Pharma have won U.S. Food and Drug Administration priority review for their applications seeking expanded approval of their Keytruda/Padcev drug combination in certain ...

Pfizer and Astellas have received the US Food and Drug Administration (FDA) acceptance for priority review of their ...

The healthcare giant has been investing heavily in its future growth.

The FDA has scolded Pfizer over Facebook ads for the cancer drug Adcetris, accusing the Big Pharma of failing to adequately ...

Global drug maker Pfizer (PFE) and biotech firm Amgen (AMGN), each valued at over HK$1T ($153B), are among 22 strategic ...

Pfizer, by contrast, appears diversified but diffuse—its pipeline may contain value, but that value is not yet organized into ...

A $500,000 retirement portfolio spread across five income-focused stocks can generate a blended yield of roughly 7.4%, ...